JNJ vs KAI · P/E 17, rev $49.37B vs P/E 36, rev $594.4M
Johnson & Johnson (JNJ) versus Kadant Inc (KAI) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Kadant Inc (KAI) is a specialty industrial machinery company listed on US.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported KAI revenue for 2026-07-04 was $594.4M. Net income was $58.0M. KAI currently screens at market cap $3.69B and trailing P/E 35.6.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. KAI currently screens at market cap $3.69B and trailing P/E 35.6.
Not investment advice. Open the JNJ and KAI stock pages for the full models.
Not investment advice.